Aurobindo Pharma gets final nod for Sumatriptan Succinate from USFDA

Hyderabad headquartered Aurobindo Pharma has announced that its tentatively approved Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate tablets 25 mg, 50 mg and 100 mg has received the final approval from the United State Food & Drug Administration (USFDA).

These tablets are the generic equivalent of Glaxo Smith Kline’s Imitrex tablets 25 mg, 50 mg and 100 mg and are indicated for the treatment of acute migraine headaches and falls under the Central Nervous System (CNS) therapeutic segment, the company mentioned in its filing with the BSE.

The company has further said that the product has also been shipped for commercial launch.

Last week, the pharma major had received the final approval for Carisoprodol Tablets USP 500 mg from the USFDA.